{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:39:18Z","timestamp":1773470358485,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005967","name":"Linnaeus University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted therapies for chronic myeloid leukaemia (CML) are effective, but rarely curative. Patients typically require treatment indefinitely, which gives ample time for drug resistance to evolve. Drug resistance issues are one of the main causes of death owing to CML, thus any means of preventing resistance are of importance. Drug rotations, wherein treatment is switched periodically between different drugs are one such option, and have been theorized to delay the onset of resistance. In vitro testing of drug rotation therapy is a first step towards applying it in animal or human trials. We developed a method for testing drug rotation protocols in CML cell lines based around culturing cells with a moderate amount of inhibitors interspersed with washing procedures and drug swaps. Drug rotations of imatinib and ponatinib were evaluated in a CML specific cell line, KCL-22. The growth of KCL-22 cells was initially reduced by a drug rotation, but the cells eventually adapted to the protocol. Our results show that ponatinib in a drug rotation temporarily sensitizes the cells to imatinib, but the effect is short-lived and is eventually lost after a few treatment cycles. Possible explanations for this observation are discussed.<\/jats:p>","DOI":"10.1038\/s41598-022-09048-5","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T10:03:15Z","timestamp":1648202595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model"],"prefix":"10.1038","volume":"12","author":[{"given":"H. Jonathan G.","family":"Lindstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"9048_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1634\/theoncologist.2007-0090","volume":"13","author":"T Fojo","year":"2008","unstructured":"Fojo, T. Commentary: Novel therapies for cancer: Why dirty might be better. The Oncologist 13, 277\u2013283. https:\/\/doi.org\/10.1634\/theoncologist.2007-0090 (2008).","journal-title":"The Oncologist"},{"key":"9048_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306\u2013313. https:\/\/doi.org\/10.1038\/nature10762 (2012).","journal-title":"Nature"},{"key":"9048_CR3","doi-asserted-by":"publisher","first-page":"6727","DOI":"10.1039\/d0cc02164d","volume":"56","author":"MJ D\u00e1vila-Rodr\u00edguez","year":"2020","unstructured":"D\u00e1vila-Rodr\u00edguez, M. J. et al. Is breaking of a hydrogen bond enough to lead to drug resistance?. Chem. Commun. 56, 6727\u20136730. https:\/\/doi.org\/10.1039\/d0cc02164d (2020).","journal-title":"Chem. Commun."},{"key":"9048_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880. https:\/\/doi.org\/10.1126\/science.1062538 (2001).","journal-title":"Science"},{"key":"9048_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 12, 513\u2013526. https:\/\/doi.org\/10.1038\/nrc3317 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"9048_CR6","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.v96.10.3343","volume":"96","author":"MWN Deininger","year":"2000","unstructured":"Deininger, M. W. N., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343\u20133356. https:\/\/doi.org\/10.1182\/blood.v96.10.3343 (2000).","journal-title":"Blood"},{"key":"9048_CR7","doi-asserted-by":"publisher","unstructured":"Soverini, S., Mancini, M., Bavaro, L., Cavo, M. & Martinelli, G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol. Cancer 17, https:\/\/doi.org\/10.1186\/s12943-018-0780-6 (2018).","DOI":"10.1186\/s12943-018-0780-6"},{"key":"9048_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","volume":"25","author":"E Jabbour","year":"2011","unstructured":"Jabbour, E., Parikh, S. A., Kantarjian, H. & Cortes, J. Chronic myeloid leukemia: Mechanisms of resistance and treatment. Hematol. Oncol. Clin. North America 25, 981\u2013995. https:\/\/doi.org\/10.1016\/j.hoc.2011.09.004 (2011).","journal-title":"Hematol. Oncol. Clin. North America"},{"key":"9048_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini, S. et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: A position paper. J. Hematol. Oncol. 12, 131 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"9048_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance. Cancer Cell 16, 401\u2013412. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028 (2009).","journal-title":"Cancer Cell"},{"key":"9048_CR11","doi-asserted-by":"publisher","unstructured":"Lindstr\u00f6m, H. J.\u00a0G. & Friedman, R. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. BMC Cancer 20, https:\/\/doi.org\/10.1186\/s12885-020-06782-9 (2020).","DOI":"10.1186\/s12885-020-06782-9"},{"key":"9048_CR12","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.ccr-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic, D. & Apperley, J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin. Cancer Res. 15, 7519\u20137527. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-1068 (2009).","journal-title":"Clin. Cancer Res."},{"key":"9048_CR13","doi-asserted-by":"publisher","first-page":"88021","DOI":"10.18632\/oncotarget.21406","volume":"8","author":"S Galimberti","year":"2017","unstructured":"Galimberti, S. et al. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget 8, 88021\u201388033 (2017).","journal-title":"Oncotarget"},{"key":"9048_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428190701713689","volume":"49","author":"S Li","year":"2008","unstructured":"Li, S. Src-family kinases in the development and therapy of philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia & Lymphoma 49, 19\u201326. https:\/\/doi.org\/10.1080\/10428190701713689 (2008).","journal-title":"Leukemia Lymphoma"},{"key":"9048_CR15","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","volume":"114","author":"E Jabbour","year":"2009","unstructured":"Jabbour, E. et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114, 2037\u20132043. https:\/\/doi.org\/10.1182\/blood-2009-01-197715 (2009).","journal-title":"Blood"},{"key":"9048_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am. J. Hematol. 95, 691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792 (2020).","journal-title":"Am. J. Hematol."},{"key":"9048_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.semcancer.2005.07.002","volume":"15","author":"DWNL Komarova","year":"2005","unstructured":"Komarova, D. W. N. L. Emergence and prevention of resistance against small molecule inhibitors. Semin. Cancer Biol. 15, 506\u2013514. https:\/\/doi.org\/10.1016\/j.semcancer.2005.07.002 (2005).","journal-title":"Semin. Cancer Biol."},{"key":"9048_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature 543, 733\u2013737. https:\/\/doi.org\/10.1038\/nature21702 (2017).","journal-title":"Nature"},{"key":"9048_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide, C. A. et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36, 431-443.e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.004 (2019).","journal-title":"Cancer Cell"},{"key":"9048_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3934\/mbe.2011.8.289","volume":"8","author":"NL Komarova","year":"2011","unstructured":"Komarova, N. L. Mathematical modeling of cyclic treatments of chronic myeloid leukemia. Math. Biosci. Eng. 8, 289\u2013306. https:\/\/doi.org\/10.3934\/mbe.2011.8.289 (2011).","journal-title":"Math. Biosci. Eng."},{"key":"9048_CR21","doi-asserted-by":"publisher","unstructured":"Bozic, I. et\u00a0al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, https:\/\/doi.org\/10.7554\/elife.00747 (2013).","DOI":"10.7554\/elife.00747"},{"key":"9048_CR22","doi-asserted-by":"publisher","unstructured":"Lindstr\u00f6m, H. J.\u00a0G., de\u00a0Wijn, A.\u00a0S. & Friedman, R. Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia. BMC Cancer 19, https:\/\/doi.org\/10.1186\/s12885-019-5690-5 (2019).","DOI":"10.1186\/s12885-019-5690-5"},{"key":"9048_CR23","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","volume":"285","author":"H Yuan","year":"2009","unstructured":"Yuan, H. et al. Bcr-abl gene expression is required for its mutations in a novel kcl-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J. Biol. Chem. 285, 5085\u201396. https:\/\/doi.org\/10.1074\/jbc.M109.039206 (2009).","journal-title":"J. Biol. Chem."},{"key":"9048_CR24","doi-asserted-by":"publisher","unstructured":"Yang, J., Lindstr\u00f6m, H. J. G. & Friedman, R. Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-021-01856-5 (2021).","DOI":"10.1186\/s12935-021-01856-5"},{"key":"9048_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12859-020-03887-7","volume":"21","author":"HJG Lindstr\u00f6m","year":"2020","unstructured":"Lindstr\u00f6m, H. J. G., de Wijn, A. S. & Friedman, R. Inferring time-dependent growth rates in cell cultures undergoing adaptation. BMC Bioinf. 21, 583 (2020).","journal-title":"BMC Bioinform."},{"key":"9048_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","volume":"1863","author":"PS Georgoulia","year":"2019","unstructured":"Georgoulia, P. S., Todde, G., Bjelic, S. & Friedman, R. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia. Biochim. Biophys. Acta Gen. Subj. 1863, 732\u2013741 (2019).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"9048_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11523-020-00741-x","volume":"15","author":"I Tusa","year":"2020","unstructured":"Tusa, I. et al. In Vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor\/stem cell features. Target Oncol 15, 659\u2013671 (2020).","journal-title":"Target Oncol."},{"key":"9048_CR28","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1535-7163.mct-12-0302","volume":"11","author":"R Sen","year":"2012","unstructured":"Sen, R. et al. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol. Cancer Ther. 11, 2033\u20132044. https:\/\/doi.org\/10.1158\/1535-7163.mct-12-0302 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"9048_CR29","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/leu.2015.35","volume":"29","author":"L Lu","year":"2015","unstructured":"Lu, L., Saunders, V. A., Leclercq, T. M., Hughes, T. P. & White, D. L. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia 29, 1792\u20131794. https:\/\/doi.org\/10.1038\/leu.2015.35 (2015).","journal-title":"Leukemia"},{"key":"9048_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2016.179","volume":"31","author":"LN Eadie","year":"2017","unstructured":"Eadie, L. N. et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia 31, 75\u201382 (2017).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09048-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:12:30Z","timestamp":1669338750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09048-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9048"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09048-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5164"}}